

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM604133

| | | | |
|---|------------------------------|-----------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Midcap Financial Trust | | 10/15/2020 | Corporation: MARYLAND |
| RECEIVING PARTY DATA | | | |
| Name: | Evolve Biologics Inc. | | |
| Street Address: | 420 Ambassador Drive | | |
| City: | Mississauga, Ontario | | |
| State/Country: | CANADA | | |
| Postal Code: | L5T 2J3 | | |
| Entity Type: | Corporation: CANADA | | |
| PROPERTY NUMBERS Total: 5 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 86039785 | PLASMACAP | |
| Serial Number: | 86019802 | PLASMACAP EBA | |
| Serial Number: | 86019797 | PLASMACAP EBA | |
| Serial Number: | 87671420 | EVOLVE BIOLOGICS | |
| Serial Number: | 87717949 | EVOLVE BIOLOGICS | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 612-915-9636 | | |
| Email: | jurzedowski@bitlaw.com | | |
| Correspondent Name: | James Urzedowski | | |
| Address Line 1: | 225 South 6th Street | | |
| Address Line 2: | Suite 1750 | | |
| Address Line 4: | Minneapolis, MINNESOTA 55402 | | |
| NAME OF SUBMITTER: | James Urzedowski | | |
| SIGNATURE: | /James M. Urzedowski/ | | |
| DATE SIGNED: | 10/21/2020 | | |
| Total Attachments: 4 | | | |

OP \$140.00 86039785

source=20-10-15-6167-Evolve-Biologic-Release#page1.tif
source=20-10-15-6167-Evolve-Biologic-Release#page2.tif
source=20-10-15-6167-Evolve-Biologic-Release#page3.tif
source=20-10-15-6167-Evolve-Biologic-Release#page4.tif

**EVOLVE BIOLOGICS INC.
RELEASE AND DISCHARGE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY**

RECITALS:

- A. Evolve Biologics Inc. (“**Evolve**”), the successor-in-title of Therapure Biopharma Inc. (“**Therapure**”), is the owner of: (i) the trademarks set forth in Exhibit A, the registrations and applications for the trademarks identified therein and the underlying goodwill of said trade marks (collectively, the “**Trademarks**”); and (ii) the patent applications and issued patents applications set forth in Exhibit A (collectively, the “**Patents**”, and together with the Trademarks, the “**Intellectual Property**”).
- B. Therapure entered into an intellectual property security agreement dated as of November 20, 2015 in favour of Midcap Financial Trust, in its capacity as administrative agent (the “**Agent**”) (as amended, modified, supplemented or restated from time to time, “**IP Security Agreement No. 1**”) under which Therapure granted to the Agent, a security interest in some of the Intellectual Property, as security for its obligations under a certain credit and security agreement.
- C. Evolve entered into an intellectual property security agreement dated as of October 22, 2019 in favour of the Agent (as amended, modified, supplemented or restated from time to time, “**IP Security Agreement No. 2**”, and collectively with IP Security Agreement No. 1, the “**IP Security Agreements**”) under which Evolve granted to the Agent, a security interest in some of the Intellectual Property, as security for its obligations under a certain credit and security agreement.
- D. All of the obligations secured by the IP Security Agreements have been discharged and paid in full.
- E. The Agent has agreed to issue this document for the purposes of evidencing the foregoing and discharging all security interests registered against the Intellectual Property.

NOW THEREFORE for good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Agent hereby irrevocably and unconditionally releases and discharges to and in favour of Therapure and Evolve, and their respective successors and assigns each and every security interest, lien, mortgage, charge, pledge, assignment and other encumbrance (collectively, “**Liens**”) created under each and every mortgage, charge or security agreement made by Therapure and Evolve in favour of the Agent over the Intellectual Property and the Agent hereby authorizes Therapure and Evolve, and their respective successors and assigns and their respective solicitors and agents to discharge all registrations of such Liens made against the Intellectual Property.

[THE REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK.]

DATED at Bethesda, MD this 15th day of October, 2020.

MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By: 
Name: Maurice Amsellem
Title: Authorized Signatory

EXHIBIT A

**TRADE MARK APPLICATIONS AND/OR REGISTRATIONS
OWNED BY EVOLVE BIOLOGICS INC.**

Canada

| Trademark | Application No. | Filing Date | Registration No. | Registration Date |
|------------------------------|------------------------|--------------------|-------------------------|--------------------------|
| PLASMACAP | 1638988 | 08/09/2013 | TMA1031710 | 06/25/2019 |
| PLASMACAP EBA | 1632165 | 06/21/2013 | TMA1025512 | 06/17/2019 |
| PLASMACAP EBA & Design | 1632163 | 06/21/2013 | TMA1025470 | 06/17/2019 |
| EVOLVE BIOLOGICS | 1866274 | 11/03/2017 | TMA1067699 | 02/01/2020 |
| EVOLVE BIOLOGICS & Design | 1872328 | 12/11/2017 | TMA1066237 | 12/12/2019 |

United States

| Trademark | Serial No. | Filing Date | Registration No. | Registration Date |
|------------------------------|-------------------|--------------------|-------------------------|--------------------------|
| PLASMACAP | 86/039,785 | 08/16/2013 | N/A | N/A |
| PLASMACAP EBA | 86/019,802 | 07/25/2013 | N/A | N/A |
| PLASMACAP EBA & Design | 86/019,797 | 07/25/2013 | N/A | N/A |
| EVOLVE BIOLOGICS | 87/671,420 | 11/03/2017 | N/A | N/A |
| EVOLVE BIOLOGICS & Design | 87/717,949 | 12/12/2017 | N/A | N/A |

**PATENT APPLICATIONS AND/OR ISSUED PATENTS
OWNED BY EVOLVE BIOLOGICS INC.**

Canada

| Title | Application No. | Filing Date | Patent No. | Issue Date |
|---|------------------------|--------------------|-------------------|-------------------|
| HEMOGLOBIN-TARGETED DRUG DELIVERY FOR THE TREATMENT OF CANCER | 3028589 | 06/21/2017 | N/A | N/A |
| METHOD FOR PURIFICATION OF ALBUMIN | 3058234 | 03/16/2018 | N/A | N/A |

United States

| Title | Serial No. | Filing Date | Patent No. | Issue Date |
|---|-------------------|--------------------|-------------------|-------------------|
| HEMOGLOBIN-TARGETED DRUG DELIVERY FOR THE TREATMENT OF CANCER | 16/310,197 | 06/21/2017 | N/A | N/A |
| METHOD FOR PURIFICATION OF ALBUMIN | 16/492,766 | 09/20/ 2019 | N/A | N/A |